A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome

Hypertension in Pregnancy

Volumn 35, Issue 3, 2016, Pages 295-305

  Stepan, H ^a   Hund, M ^b   Gencay, M ^b   Denk, B ^c   Dinkel, C ^c   Kaminski, W E ^d   Wieloch, P ^d   Semus, B ^d   Meloth, T ^d   Droge L A ^e   Verlohren, S ^e  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Roche Diagnostics Ltd   (Switzerland)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d Bioscientia Center for Human Genetics   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Diagnosis; HELLP syndrome; placental growth factor (PlGF); preeclampsia; soluble fms like tyrosine kinase 1 (sFlt 1)

Indexed keywords

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HELLP SYNDROME; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MATERNAL BLOOD; MULTICENTER STUDY; PREECLAMPSIA; SENSITIVITY AND SPECIFICITY; ADULT; BLOOD; CASE CONTROL STUDY; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDY; YOUNG ADULT;

BIOLOGICAL MARKER; FLT1 PROTEIN, HUMAN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HELLP SYNDROME; HUMANS; PLACENTA GROWTH FACTOR; PRE-ECLAMPSIA; PREGNANCY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84961922841     PISSN: 10641955     EISSN: 15256065     Source Type: Journal    
DOI: 10.3109/10641955.2016.1141214     Document Type: Article

References (29)

1. U.Hogberg The World Health Report 2005:‘‘make every mother and child count’’ – including Africans. Scand J Public Health. 2005;33:409–411.
2. J.G.Ray, M.J.Vermeulen, M.J.Schull, et al. Cardiovascular health after maternal placental syndromes (CHAMPS):population-based retrospective cohort study. Lancet. 2005;366:1797–1803.
3. L.Duley The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33:130–137.
4. E.A.Steegers, P.von Dadelszen, J.J.Duvekot, et al. Pre-eclampsia. Lancet. 2010;376:631–644.
5. M.Noris, N.Perico, G.Remuzzi Mechanisms of disease:pre-eclampsia. Nat Clin Pract Nephrol. 2005;1:98–114.
6. J.M.Roberts, G.D.Pearson, J.A.Cutler, et al. Summary of the NHBLI working group on research on hypertension during pregnancy. Hypertens Pregnancy. 2003;22:109–127.
7. B.M.Sibai, C.L.Stella Diagnosis and management of atypical preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200:481.e1–481.e7.
8. ACOG Task Force on Hypertension in Pregnancy. Hypertension in Pregnancy. Obstet Gynecol. 2013;122:1122–1131.
9. S.M.Oliveira, E.A.Arcuri, J.L.Santos Cuff width influence on blood pressure measurement during the pregnant-puerperal cycle. J Adv Nurs. 2002;38:180–189.
10. L.W.Reinders, C.N.Mos, C.Thornton, et al. Time poor:rushing decreases the accuracy and reliability of blood pressure measurement technique in pregnancy. Hypertens Pregnancy. 2006;25:81–91.
11. S.E.Maynard, J.Y.Min, J.Merchan, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658.
12. T.Chaiworapongsa, P.Chaemsaithong, L.Yeo, et al. Pre-eclampsia part 1:current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466–480.
13. S.Verlohren, I.Herraiz, O.Lapaire, et al. New gestational phase–specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346–352.
14. R.J.Levine, S.E.Maynard, C.Qian, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672–683.
15. E.Shibata, A.Rajakumar, R.W.Powers, et al. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for gestational-age neonates:relationship to circulating placental growth factor. J Clin Endocrinol Metab. 2005;90:4895–4903.
16. S.J.Benton, Y.Hu, F.Xie, et al. Angiogenic factors as diagnostic tests for preeclampsia:a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205:469–471.
17. J.Schiettecatte, H.Russcher, E.Anckaert, et al. Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia. Clin Biochem. 2010;43:768–770.
18. P.I.Gómez-Arriaga, I.Herraiz, E.A.López-Jiménez, et al. Uterine artery Doppler and sFlt-1/PlGF ratio:usefulness in diagnosis of pre-eclampsia. Ultrasound Obstet Gynecol. 2013;41:530–537.
19. I.Álvarez-Fernández, B.Prieto, V.Rodríguez, et al. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52(8):1159–1168.
20. S.Rana, C.E.Powe, S.Salahuddin, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected pre-eclampsia. Circulation. 2012;125:911–919.
21. S.Verlohren, A.Galindo, D.Schlembach, et al. An automated method for the determination of the sFlt-1/PlGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161.e1–161.e11.
22. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1–S22.
23. Roche Diagnostics GmbH:Elecsys PlGF Immunoassay, Package Insert. 2015-11, V 8.0.Available at:https://pim-eservices.roche.com/(S(aou3rto4kqllwta02cqhham0))/pi/en/Documents/GetDocument?documentId=b4d1d21e-03cf-e411-19b6-00215a9b0ba8. Accessed February 17, 2016.
24. T.Sing, O.Sander, N.Beerenwinkel, et al. ROCR:visualizing classifier performance in R. Bioinformatics. 2005;21:3940–3941.
25. E.R.DeLong, D.M.DeLong, D.L.Clarke-Pearson Comparing the areas under two or more correlated receiver operating characteristic curves:a nonparametric approach. Biometrics. 1988;44:837–845.
26. A.Ohkuchi, C.Hirashima, K.Takahashi, et al. Onset threshold of the plasma levels of soluble fms-like tyrosine kinase 1/placental growth factor ratio for predicting the imminent onset of preeclampsia within 4 weeks after blood sampling at 19–31 weeks of gestation. Hypertens Res. 2013;36:1073–1080.
27. S.Verlohren, I.Herraiz, O.Lapaire, et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol. 2012;206:58.e1–58e8.
28. H.Stepan, I.Herraiz, D.Schlembach, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy:implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45:241–246.
29. J.Lai, S.Garcia-Tizon Larroca, G.Peeva, et al. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks’ gestation. Fetal Diagn Ther. 2014;35:240–248.